Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging

详细信息    查看全文

• 作者：Kristina Buder (8) (9)
  Constantin Lapa (10)
  Michael C Kreissl (10) (11)
  Andreas Schirbel (10)
  Ken Herrmann (10)
  Alexander Schnack (12)
  Eva-Bettina Br枚cker (8)
  Matthias Goebeler (8)
  Andreas K Buck (10)
  J眉rgen C Becker (13) (8)
  
  8. Department of Dermatology ; Venereology and Allergology ; University Hospital W眉rzburg ; Josef-Schneider-Strasse 2 ; 97080 ; W眉rzburg ; Germany
  9. Comprehensive Cancer Center Mainfranken ; University Hospital W眉rzburg ; Josef-Schneider-Strasse 6 ; 97080 ; W眉rzburg ; Germany
  10. Department of Nuclear Medicine ; University Hospital W眉rzburg ; Oberd眉rrbacher Strasse 6 ; 97080 ; W眉rzburg ; Germany
  11. Department of Nuclear Medicine ; Central Hospital of Augsburg ; Stenglinstr.2 ; 86156 ; Augsburg ; Germany
  12. Department of Radiology ; University Hospital W眉rzburg ; Oberd眉rrbacher Strasse 6 ; 97080 ; W眉rzburg ; Germany
  13. Department of General Dermatology ; Medical University Graz ; Auenbrugger Platz 1 ; 8036 ; Graz ; Austria
  
• 关键词：Merkel cell carcinoma ; Molecular imaging ; Somatostatin receptor expression ; Positron emission tomography
• 刊名：BMC Cancer
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：14
• 期：1
• 全文大小：944 KB
• 参考文献：1. Schrama, D, Ugurel, S, Becker, JC (2012) Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol 24: pp. 141-149 CrossRef
  2. Agelli, M, Clegg, LX, Becker, JC, Rollison, DE (2010) The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer 34: pp. 14-37 CrossRef
  3. Durani, BK, Klein, A, Henze, M, Haberkorn, U, Hartschuh, W (2003) Somatostatin analogue scintigraphy in Merkel cell tumours. Br J Dermatol 148: pp. 1135-1140 CrossRef
  4. Fantini, F, Johansson, O (1995) Neurochemical markers in human cutaneous Merkel cells. An immunohistochemical investigation. Exp Dermatol 4: pp. 365-371 CrossRef
  5. Lemos, BD, Storer, BE, Iyer, JG, Phillips, JL, Bichakjian, CK, Fang, LC, Johnson, TM, Liegeois-Kwon, NJ, Otley, CC, Paulson, KG, Ross, MI, Yu, SS, Zeitouni, NC, Byrd, DR, Sondak, VK, Gershenwald, JE, Sober, AJ, Nghiem, P (2010) Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63: pp. 751-761 CrossRef
  6. Becker, JC, Assaf, C, Vordermark, D, Reske, SN, Hense, J, Dettenborn, T, Seitz, O, Grabbe, S (2013) German guideline Merkel Cell Carcinoma. JDDG Suppl. 3: pp. 31-38 CrossRef
  7. Boccara, O, Girard, C, Mortier, L, Bens, G, Saiag, P, Guillot, B (2012) Guidelines for the diagnosis and treatment of Merkel cell carcinoma - Cutaneous Oncology Group of the French Society of Dermatology. Eur J Dermatol 22: pp. 375-379
  8. Colgan, MB, Tarantola, TI, Weaver, AL, Wiseman, GA, Roenigk, RK, Brewer, JD, Otley, CC (2012) The predictive value of imaging studies in evaluating regional lymph node involvement in Merkel cell carcinoma. J Am Acad Dermatol 67: pp. 1250-1256 CrossRef
  9. Sarnaik, AA, Zager, JS, Cox, LE, Ochoa, TM, Messina, JL, Sondak, VK (2010) Routine omission of sentinel lymph node biopsy for merkel cell carcinoma < = 1聽cm is not justified. J Clin Oncol 28: pp. e7 CrossRef
  10. Schwartz, JL, Griffith, KA, Lowe, L, Wong, SL, McLean, SA, Fullen, DR, Lao, CD, Hayman, JA, Bradford, CR, Rees, RS, Johnson, TM, Bichakjian, CK (2011) Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol 29: pp. 1036-1041 CrossRef
  11. Stokes, JB, Graw, KS, Dengel, LT, Swenson, BR, Bauer, TW, Slingluff, CL, Ledesma, EJ (2009) Patients with Merkel cell carcinoma tumors <鈥塷r =鈥?.0聽cm in diameter are unlikely to harbor regional lymph node metastasis. J Clin Oncol 27: pp. 3772-3777 CrossRef
  12. Belhocine, T, Pierard, GE, Fruhling, J, Letesson, G, Bolle, S, Hustinx, R, Dargent, JL, Flamen, P, Rigo, P (2006) Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep 16: pp. 347-352
  13. Concannon, R, Larcos, GS, Veness, M (2010) The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia. J Am Acad Dermatol 62: pp. 76-84 CrossRef
  14. Hawryluk, EB, O鈥橰egan, KN, Sheehy, N, Guo, Y, Dorosario, A, Sakellis, CG, Jacene, HA, Wang, LC (2013) Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and women鈥檚 cancer center. J Am Acad Dermatol 68: pp. 592-599 CrossRef
  15. Maury, G, Dereure, O, Du-Thanh, A, Mariano-Goulart, D, Guillot, B (2011) Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients. J Eur Acad Dermatol Venereol 25: pp. 1420-1427 CrossRef
  16. Peloschek, P, Novotny, C, Mueller-Mang, C, Weber, M, Sailer, J, Dawid, M, Czerny, C, Dudczak, R, Kletter, K, Becherer, A (2010) Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET. Eur J Radiol 73: pp. 317-323 CrossRef
  17. Siva, S, Byrne, K, Seel, M, Bressel, M, Jacobs, D, Callahan, J, Laing, J, Macmanus, MP, Hicks, RJ (2013) 18聽F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience. J Nucl Med 54: pp. 1223-1229 CrossRef
  18. Kwekkeboom, DJ, Hoff, AM, Lamberts, SW, Oei, HY, Krenning, EP (1992) Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases. Arch Dermatol 128: pp. 818-821 CrossRef
  19. Hofmann, M, Maecke, H, Borner, R, Weckesser, E, Schoffski, P, Oei, L, Schumacher, J, Henze, M, Heppeler, A, Meyer, J, Knapp, H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28: pp. 1751-1757 CrossRef
  20. Boy, C, Heusner, TA, Poeppel, TD, Redmann-Bischofs, A, Unger, N, Jentzen, W, Brandau, W, Mann, K, Antoch, G, Bockisch, A, Petersenn, S (2011) 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 38: pp. 1224-1236 CrossRef
  21. Miederer, M, Seidl, S, Buck, A, Scheidhauer, K, Wester, HJ, Schwaiger, M, Perren, A (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36: pp. 48-52 CrossRef
  22. Gabriel, M, Decristoforo, C, Kendler, D, Dobrozemsky, G, Heute, D, Uprimny, C, Kovacs, P, von Guggenberg, E, Bale, R, Virgolini, IJ (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: pp. 508-518 CrossRef
  23. Schneider, C, Schlaak, M, Bludau, M, Markiefka, B, Schmidt, MC (2012) 68Ga-DOTATATE-PET/CT positive metastatic lymph node in a 69-year-old woman with Merkel cell carcinoma. Clin Nucl Med 37: pp. 1108-1111 CrossRef
  24. Epstude, M, Tornquist, K, Riklin, C, di Lenardo, F, Winterhalder, R, Hug, U, Strobel, K (2013) Comparison of 18聽F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging in Metastasized Merkel cell carcinoma. Clin Nucl Med 38: pp. 283-284 CrossRef
  25. Breeman, WA, de Blois, E, Sze Chan, H, Konijnenberg, M, Kwekkeboom, DJ, Krenning, EP (2011) (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 41: pp. 314-321 CrossRef
  26. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, Dancey, J, Arbuck, S, Gwyther, S, Mooney, M, Rubinstein, L, Shankar, L, Dodd, L, Kaplan, R, Lacombe, D, Verweij, J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: pp. 228-247 CrossRef
  27. Young, H, Baum, R, Cremerius, U, Herholz, K, Hoekstra, O, Lammertsma, AA, Pruim, J, Price, P, Canc, EORT (1999) Measurement of clinical and subclinical tumour response using [F-18]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 35: pp. 1773-1782 CrossRef
  28. Putzer, D, Gabriel, M, Henninger, B, Kendler, D, Uprimny, C, Dobrozemsky, G, Decristoforo, C, Bale, RJ, Jaschke, W, Virgolini, IJ (2009) Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50: pp. 1214-1221 CrossRef
  29. Bailey, TL, Fung, MA, Gandour-Edwards, R, Ellis, WG, Schrot, RJ (2011) Clinical emergence of neurometastatic merkel cell carcinoma: a surgical case series and literature review. J Neurooncol 102: pp. 147-155 CrossRef
  30. Guitera-Rovel, P, Lumbroso, J, Gautier-Gougis, MS, Spatz, A, Mercier, S, Margulis, A, Mamelle, G, Kolb, F, Lartigau, E, Avril, MF (2001) Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases. Ann Oncol 12: pp. 807-811 CrossRef
  31. Voog, E, Biron, P, Martin, JP, Blay, JY (1999) Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85: pp. 2589-2595 CrossRef
  32. di Bartolomeo, M, Bajetta, E, Buzzoni, R, Mariani, L, Carnaghi, C, Somma, L, Zilembo, N, di Leo, A (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group. Cancer 77: pp. 402-408 CrossRef
  33. Fakiha, M, Letertre, P, Vuillez, JP, Lebeau, J (2010) Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther 6: pp. 382-384 CrossRef
  34. Meier, G, Waldherr, C, Herrmann, R, Maecke, H, Mueller-Brand, J, Pless, M (2004) Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. a case report. Oncology 66: pp. 160-163 CrossRef
  35. Salavati, A, Prasad, V, Schneider, CP, Herbst, R, Baum, RP (2012) Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med 26: pp. 365-369 CrossRef
  36. Schmidt, MC, Uhrhan, K, Markiefka, B, Hasselbring, L, Schlaak, M, Cremer, B, Kunze, S, Baum, RP, Dietlein, M (2012) (68)Ga-DotaTATE PET-CT followed by peptide receptor radiotherapy in combination with capecitabine in two patients with merkel cell carcinoma. Int J Clin Exp Med 5: pp. 363-366
  37. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/268/prepub
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Merkel cell carcinoma (MCC) is a rare cutaneous neoplasm with increasing incidence, aggressive behavior and poor prognosis. Somatostatin receptors (SSTR) are expressed in MCC and represent a potential target for both imaging and treatment. Methods To non-invasively assess SSTR expression in MCC using PET and the radiotracers [68Ga]DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) or -octreotate (DOTATATE) as surrogate for tumor burden. In 24 patients with histologically proven MCC SSTR-PET was performed and compared to results of computed tomography (CT). Results SSTR-PET detected primary and metastatic MCC lesions. On a patient-based analysis, sensitivity of SSTR-PET was 73% for nodal metastases, 100% for bone, and 67% for soft-tissue metastases, respectively. Notably, brain metastases were initially detected by SSTR-PET in 2 patients, whereas liver and lung metastases were diagnosed exclusively by CT. SSTR-PET showed concordance to CT results in 20 out of 24 patients. Four patients (17%) were up-staged due to SSTR-PET and patient management was changed in 3 patients (13%). Conclusion SSTR-PET showed high sensitivity for imaging bone, soft tissue and brain metastases, and particularly in combination with CT had a significant impact on clinical stage and patient management.